Genascence begins Phase Ib gene therapy trial for knee osteoarthritis

Genascence has commenced its Phase Ib clinical trial designed to evaluate GNSC-001, a gene therapy for the treatment of knee osteoarthritis (OA).

The randomised, double-blinded, placebo-controlled, dose-ranging trial, named DONATELLO, is currently enrolling patients across ten clinical centres in the US.